AstraZeneca has entered into a multi-year strategic collaboration with BostonGene to integrate its multimodal AI foundation model for tumor and immune biology across AZ’s oncology R&D portfolio. Under the agreement, BostonGene’s platform will provide patient-level predictive insights on safety and efficacy for early-stage trials, leveraging pre-trained models with cfRNA and tumor microenvironment profiling. AZ expects this partnership to accelerate its development timelines by up to six months per program and reduce trial attrition risk by approximately 20%, enhancing the company’s ability to select optimal patient subgroups and refine biomarker strategies prior to registration studies.

In the Phase 3 TULIP-SC trial, AZ’s subcutaneous formulation of Saphnelo (anifrolumab) achieved a 56.2% reduction in disease activity versus 37.1% for placebo at Week 52, meeting the primary endpoint with a p-value under 0.001. The self-injectable regimen was well tolerated, with serious adverse events reported in 8.5% of treated patients compared to 11.3% in the control arm. With approvals already secured in over 70 countries and more than 40,000 patients treated globally on IV formulations, AZ plans to submit the SC data to regulators in H2 2024 to expand patient access and drive peak annual sales toward the high-single-digit billion dollar range by 2026.